September 27, 2006 – Late in the day, the FDA approved Vectibix from Amgen for colorectal cancer; Merck extended its collaboration with FoxHollow, buying $95 million of FoxHollow stock; Arena Pharma and Ortho-McNeill will extend their partnership; Avant received $750,000 to develop a typhoid vaccine; Elan signed a Alzheimer’s collaboration with Transition; Axcan in-licensed a controlled-release proton pump inhibitor from AGI Therapeutics; Athenagen raised $50 million in a B round of financing; Genentech moved higher after Jeffries upped its target on the stock; and BioCryst rose ahead of a presentation on its avian flu drug. The Centient Biotech 200™ climbed a very large 61 points to 3822.76, a gain of 1.63%. More details...
